GET HELP NOW! Addiction Specialist Available 24/7

1.855.228.9901

all calls are 100% confidential

Q Health Advisory Board

Q Health Services, Inc. is proud of the exceptional contributions provided by members of its Advisory Board. The Advisory Board is co-chaired by Q Health’s co-founders and Co-CEOs, Lawrence Hawkins and Ronen Gershon. The Advisory Board is a seven-member board, including the two board seats occupied by the board co-chairs. Advisory Board members are selected based upon each member’s ability to provide significant contributions to Q Health and its mission, vision, and strategic goals. The multidisciplinary Advisory Board is comprised of those with exceptional leadership and business skills, clinical and research expertise pertinent to the provision of behavioral healthcare services, and competencies consistent with Q Health achieving and sustaining an exemplary reputation as a behavioral healthcare provider with a national reach.

LAWRENCE HAWKINS – CO-CHIEF EXECUTIVE OFFICE

LAWRENCE  HAWKINSLawrence (Larry) Hawkins, MBA, Ph.D. (candidate), Co-Chief Executive Officer (Co-CEO) has provided C-level leadership for 12 years and a further 18 years’ experience in increasingly responsible management and leadership in diversified industries, including finance, real estate, telecommunications, and retail. Larry’s track record demonstrates a remarkable capacity to launch, build, grow, and operate businesses by harnessing a breadth of leadership competencies including strategic planning and implementation, change management, people and team development, financial and budgetary management, marketing, and cost containment. His academic credentials include a Bachelor of Science in Business Management and a Masters’ in Business Administration, both from the University of Florida. In addition, Larry is a Ph.D. candidate in Organizational Leadership from The Chicago School of Professional Psychology. A long-time resident of Southeast Florida, he has served on the Executive Association of the West Palm Beach District, the University of Florida’s President’s Council, and is a well-regarded member of the business community.

RONEN GERSHON – CO-CHIEF EXECUTIVE OFFICER

Ronan_low resRonen Gershon, Co-Chief Executive Officer (Co-CEO) has a proven record of creating and leading business at the international level across diverse sectors, including residential and commercial real estate, and finance. Ronen has provided executive leadership to diverse organizations including most recently for Q Investments where he serves as Chief Executive Officer. For over 26 years, he successfully developed, managed, and invested in projects around the world. His success is greatly due to his motivation to leave a memorable impression for generations to come on anything he gets involved with. His portfolio of work includes building and developing a 35,000 SF shopping center with 860 shops in Cyprus, as well as building over 4,000 single-family homes in the United States. His goal is to make dreams a reality for his clients and he believes in doing whatever it takes to make each client’s dream come true. For Ronen’s failure is never an option and his track record of successful projects is a clear testament to his beliefs.

SEAMAS LAGAN, BOARD MEMBER

Seamas Lagan is the CEO of Medytox Solutions, Inc. and a Q Health Advisory Board Member. Mr. Lagan brings over 20 years of experience in the restructure, development, and management of startup and small companies in both the private and the public sector. He was initially retained by Medytox in May 2011 to find a new business opportunities, and has been instrumental in forming the structure of and securing the funding for Medytox to develop its current business plan. As a result of Mr. Lagan’s vision and leadership, Medytox has grown from a $5MM company to a $100MM enterprise in just four years. Mr. Lagan has also been the CEO of two Medytox subsidiaries since their inception: one that manages the sales and marketing efforts, and a separate subsidiary that enters into agreement with or completes the acquisitions and development of clinical laboratories.